Despite the development of innovative therapies against cancer such as targeted therapies and immune checkpoint inhibitors (ICI), the heterogeneity of tumors, their resistance to therapies and relapses pose a real problem for patients and health authorities in terms of number of deaths per year and costs. Targeting tumor resistance and relapses represents an urgent need that THERANOVIR is currently addressing. By targeting the new complex Leptin-dependent NRP-1/OBR signaling composed by   the two proteins NRP-1 and OBR hugely reported to be  involved in the drug resistance and cancer cell stemness, THERANOVIR aims to limit therapeutic resistance and relapse by proposing NOV2  targeting  a highly drug resistant  cancer  stem-like  circulating tumor cells  (CTC) expressing a high GAG-NRP-1 (Glycosaminoglycan modified NRP-1) in combination with chemotherapy and/or immune checkpoint inhibitors (ICI) and/or Radiotherapy to enhance their efficacy thereby limiting the number of deaths and reducing costs. NOV2 can be  be proposed  naked or as radiopharmaceutical drug.